Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Clin Gastroenterol. 2017 Feb;51(2):e11–e16. doi: 10.1097/MCG.0000000000000591

Figure 3. The combination of ATRA and UDCA reduced serum ALT and bile acid intermediate C4.

Figure 3

Panel 3A: The median serum ALT level decreased from 76±55 to 46±32 U/L at 12 weeks of combined therapy, p=.01. After a 12-week washout post-ATRA and back to UDCA monotherapy, the median ALT significant increased compared to end of treatment levels (end of treatment 46±32 vs. post-washout 74±74; p=0.0006). Panel 3B: The median serum C4 level decreased at week 12 from baseline (9.8±19 to 7.9±11 ng/mL; P=.03). Panel 3C: The median serum bile acid level decreased at week 12 from baseline but did not achieve significance (24±27 vs. 9±45 umol/L, p=.2). Only 7 subjects from one of the enrolling sites had bile acid levels available for analysis.